Can Brain Natriuretic Peptide Predict Mesothelioma Outcomes?

ByHolly Zink
Can Brain Natriuretic Peptide Predict Mesothelioma Outcomes?

Researchers have been looking at a substance called Brain Natriuretic Peptide to find out if it could predict survival in patients with mesothelioma.

Mesothelioma is a rare type of cancer affecting a special lining around our organs called the mesothelium. It is linked to exposure to asbestos, a toxic material used in many buildings and products in the past. This cancer can be hard to diagnose and treat.

BNP: A Potential Lifesaver for Mesothelioma Patients

Recently, mesothelioma researchers have been looking at Brain Natriuretic Peptide (BNP). This substance is usually produced by certain cells in the heart. In cases of malignant mesothelioma, it seems also to be produced by the cancerous cells.

The researchers wanted to find out if the ratio of BNP in the fluid around the lungs compared to the amount in the blood could give them clues about how a person might fare after being diagnosed with mesothelioma in the lungs. They looked at 19 patients with mesothelioma and studied how long they survived after their diagnosis.

On average, the patients were about 67 years old, and nearly 79% of them were male. After one year, about 53% of the patients were still alive, and after two years, about 32% were still alive. The researchers looked at factors like age and overall health, but these did not seem to make a big difference in how long someone survived.

They did notice that those who did not survive as long tended to have higher levels of BNP in the fluid around the lungs, especially after two years. They also found that the ratio of BNP in the fluid compared to the blood was higher in those who did not survive as long. This means that this ratio might be a useful marker for predicting how well someone might do after a mesothelioma diagnosis.

They also looked at something called the Natriuretic Peptide Precursor B (NPPB) gene, which is related to BNP. They discovered that patients with lower levels of NPPB tended to have better survival rates compared to those with higher levels.

The researchers think that looking at the ratio of BNP in the lung fluid to the blood could be a simple and cost-effective way to predict how well someone with mesothelioma might do in the future. This could be even more helpful than some of the commonly used factors for predicting outcomes in mesothelioma cases.

Source

Tsolaki V, Zakynthinos GE, Zarogiannis S, et al. Pleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma. Clin Pract. 2023;13(5):1111-1122. Published 2023 Sep 13. doi:10.3390/clinpract13050099. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514826/

Similar Posts

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    ByAlex Strauss

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • |

    Study Lists Factors That Impact Mesothelioma Prognosis

    ByAlex Strauss

    Predicting survival in mesothelioma patients does not have to be complicated. A new Parisian study suggests that simple-to-measure factors such as patient age and the histological subtype of the mesothelioma can be highly accurate prognostic indicators. The study followed 170 patients diagnosed with malignant pleural mesothelioma between 2000 and 2010 at Saint Antoine Hospital in Paris. Patients in the study were all treated non-surgically. For each patient, a list of parameters was recorded including age, gender, tobacco use, asbestos exposure, type and duration of symptoms, BMI, C-reactive protein levels and white blood cell and platelet counts.  Inflammation of the pleura (pachypleuritis) was also noted, along with the type of diagnostic surgical procedure, histological subtype, the way in which pleurodesis was performed (for…

  • |

    Predicting Mesothelioma Outcomes with Blood Tests

    ByAlex Strauss

    Two separate teams of Japanese researchers are delving into the possibilities of blood serum indicators that could help predict outcomes in patients with malignant pleural mesothelioma. Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. Pleural mesothelioma, a cancer that starts on the lining around the lungs, is the most common form of the disease. It occurs most often in people who have inadvertently inhaled asbestos dust. Mesothelioma is highly resistant to conventional treatments. It is also difficult to predict which patients are likely to do well with standard therapies and which are not, which is referred to as prognosis. But researchers worldwide are continually searching for new ways to diagnose and predict the prognosis of patients with…

  • |

    Drop in Lung Volume Predicts Poor Mesothelioma Outcome

    ByAlex Strauss

    Decreases in lung volume may be an indicator of treatment response for patients with mesothelioma. Researchers in the U.S. and Australia reached that conclusion after studying the cases of 61 patients with malignant pleural mesothelioma and 216 CT scans taken of them during the course of their standard chemotherapy treatment. Lung volume is a measurement of the amount of air the lung processes (inhales, exhales and holds on to) during the course of a normal breath. People with malignant pleural mesothelioma, a cancer that starts on the lining around the lungs, typically experience a drop in lung volume as the pleural tumor grows and constricts or even invades one of their lungs. The new study measured changes in each mesothelioma patient’s…

  • |

    New Prognostic Tools Could Improve Mesothelioma Treatment

    ByAlex Strauss

    A pair of cancer researchers from Rome say treatment for malignant pleural mesothelioma could be improved if more clinicians considered the newest prognostic tools in their treatment planning. Pleural mesothelioma is a malignancy of the membranes that encase the lungs. It is caused by exposure to the mineral asbestos and is highly resistant to conventional cancer therapies. Many mesothelioma patients do not survive longer than 12 months from the onset of their symptoms. But Tommaso Mineo, MD, and Vincenzo Ambrogi, PhD, of the Department of Experimental Medicine and Surgery at Policlinico Tor Vergata University say newly discovered biomarkers and other tumor factors could lead to more tailored treatment and, potentially, better outcomes. “Therapy is currently guided by gross tumor characteristics and patient…

  • |

    For Some Patients Chemo Cuts Mesothelioma Survival

    ByAlex Strauss

    Asbestos disease researchers in Australia say chemotherapy at the end of life may be doing some mesothelioma patients more harm than good. The team from the Asbestos Diseases Research Institute in Rhodes, Australia analyzed the cases of 147 malignant pleural mesothelioma patients who had received compensation from the government’s Dust Diseases Board. The focus of the study was to determine the association between a variety of factors such as age, gender, geographic location, disease stage, histological subtype, length of first-line chemotherapy, and the use of chemotherapy in the last month of their lives. Among the mesothelioma patients studied, most (77%) received more than one treatment modality while 56% received only one. Chemotherapy, which continues to be the most popular first-line treatment…